SRGAP2

Across TCGA pan-cancer cohorts, SRGAP2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SRGAP2 data layer compared with 27 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SRGAP2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SRGAP2 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, CCRCC, and LSCC are the cancer types where SRGAP2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.274	0.460	.002	40	view →
CCRCC	OS	Tertile	All	0.830	1.000	.001	20	view →
LSCC	DFS	Median	III,IV	0.358	0.801	.003	12	view →
GBM	OS	Median	All	0.423	0.614	.004	4	view →
LUAD	DFS	Median	II,III,IV	0.654	0.361	.029	3	view →
HNSC	OS	Quartile	All	0.732	0.923	.040	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SRGAP2–PDAC (OS)

Open the PDAC breakdown →